Patients with nosocomial pneumonia caused by Stenotrophomonas maltophilia often receive inadequate empiric antibiotic therapy, potentially increasing mortality. Knowledge of the risk factors associated with S. maltophilia pneumonia may better guide the selection of empiric antibiotic therapy. Potential risk factors for S. maltophilia pneumonia were retrospectively analyzed for critically ill trauma patients with late-onset gram-negative pneumonia. The effects of S. maltophilia infection and inadequate empiric antibiotic therapy on patient outcomes were also assessed. By multivariate analysis, S. maltophilia pneumonia was found to be associated with cefepime exposure and tracheostomy in patients with a single pneumonia episode and with higher Injury Severity Score and pulmonary contusion in patients with multiple pneumonia episodes. S. maltophilia pneumonia was associated with increased patient morbidity; only inadequate empiric antibiotic therapy was associated with a higher mortality rate. In critically ill trauma patients with late-onset ventilator-associated pneumonia and these risk factors, empiric antibiotic therapy should include agents active against S. maltophilia.
tibiotic therapy often does not include agents active against S. maltophilia, as a result of this pathogen's intrinsic resistance to most antibiotics that are commonly used in the intensive care setting [1, 10] .
Knowledge of the risk factors for the development of S. maltophilia pneumonia would be useful in determining which patients should empirically receive antibiotics active against S. maltophilia. Although risk factors have been identified for medical ICU patients [11] and for patients with cystic fibrosis [12] , limited information is available with regard to the development of S. maltophilia pneumonia in trauma patients. Duration of mechanical ventilator support, the need for tracheostomy or air transport to the hospital, and the number of antibiotics received have been identified as being risk factors for S. maltophilia in trauma patients [13] . However, in that study, both S. maltophilia infection and S. maltophilia colonization were included, the diagnosis of pneumonia was based solely on clinical judgment, and all pneumonia cases (early and late onset) were included, which had the potential to skew risk-factor analyses. Most studies have analyzed all S. maltophilia infections [11, 13] ; however, risk factors may differ depending on the site of infection.
To further elucidate this issue, we retrospectively analyzed potential risk factors associated with the development of lateonset S. maltophilia VAP (SM-VAP) against those associated with the development of late-onset VAP caused by other gramnegative bacteria (GN-VAP). In addition, we also analyzed the effects of S. maltophilia pneumonia and inadequate empiric antibiotic therapy on patient outcomes.
METHODS
We reviewed the records of patients admitted to the trauma ICU at the Presley Memorial Trauma Center, Memphis, Tennessee, from 1 January 1997 to 31 December 1999 who received a diagnosis of pneumonia during the ICU stay. The study was approved by the University of Tennessee Institutional Review Board; informed consent was not required. Patients were included in the study if they had documented late-onset GN-VAP that occurred at least 7 days after hospital admission [14, 15] but was diagnosed within 5 days of transfer out of the ICU, if they were у18 years of age, and if they had needed mechanical ventilator support. Patients were excluded if they stayed in another hospital 12 days before admission to the ICU or if they had been transferred from the ICU to another hospital's ICU within 2 weeks of admission to the ICU at the Presley Memorial Trauma Center. Pneumonia was defined by a result of a quantitative bacterial bronchoalveolar lavage (BAL) culture of у10 5 cfu/mL, the appearance of a new or changing infiltrate on chest radiograph, and at least 2 of the following clinical signs of pneumonia: abnormal temperature (у38ЊC or !35.5ЊC), abnormal WBC count (у10,000 cells/mm 3 or р4000 cells/mm 3 or the presence of у10% immature bands), or macroscopically purulent sputum [16] .
BAL was performed via fiberoptic bronchoscopy. Briefly, the bronchoscope was advanced into the lung segment in which radiographic changes were seen or, for patients who had diffuse bilateral infiltrates, into the left lower lobe. With the bronchoscope wedged into the appropriate lung segment, 100 mL of sterile nonbacteriostatic saline was instilled into the lung in five 20-mL aliquots. The effluent was pooled and sent to the microbiology laboratory for quantitative culture. The antimicrobial susceptibility of isolates was tested by the hospital microbiology laboratory, and the results were interpreted by National Committee for Clinical Laboratory Standards guidelines [17] .
The following demographic information was retrieved from each patient's medical record for assessment of potential risk factors for S. maltophilia pneumonia: age; sex; mechanism of injury; type of injury; presence of predisposing chronic diseases (i.e., diabetes mellitus, cancer, or chronic lung disease); alcohol abuse or current use of cigarettes, as identified in the social history; Glasgow Coma Scale score [18] ; Injury Severity Score (ISS) [19] ; and chest Abbreviated Injury Scale (AIS) score [20] . The following variables were documented and assessed as risk factors associated with exposure before the development of pneumonia: duration of mechanical ventilator support; length of ICU stay; length of hospital stay; presence of tracheostomy; number and types of surgeries; previous antibiotic use; number of bronchoscopic procedures; use of respiratory therapy (aerosolized medications); type of stress-ulcer prophylactic agent administered, if any; use of glucocorticoids; whether enteral or parenteral nutrition was received; presence of a nasogastric or nasotracheal tube; presence of a chest tube; and presence of central venous catheters. Finally, the following variables were documented at the time of each pneumonia episode and assessed as risk factors: Acute Physiology and Chronic Health Evaluation (APACHE) II score [21] and multiple organ dysfunction score [22] (using worst values within previous 24 h), witnessed or suspected aspiration, WBC count, temperature, and sputum characteristics.
Data from a single case of pneumonia for each patient were included in the study analysis. For patients who experienced multiple episodes of late-onset pneumonia, only the most recent ICU-associated pneumonia episode was included in the analysis. Once S. maltophilia pneumonia developed, only that pneumonia episode was included in the analysis. We postulated that the nature of the risk factors may change over time. Therefore, we analyzed risk factors for S. maltophilia for patients who developed a single late-onset VAP episode and for patients who experienced multiple late-onset VAP episodes.
To assess the effect of S. maltophilia pneumonia on patient outcomes, the following information was retrieved from the medical record: total length of ICU and hospital stay, total duration of mechanical ventilator support, need for tracheostomy, and survival status at hospital discharge. In addition, patient outcomes were also assessed according to receipt of adequate or inadequate empiric antibiotic therapy. Empiric antibiotic therapy was considered to be adequate when all isolates found in numbers у10 5 cfu/mL on culture of a BAL sample were reported by the hospital microbiology laboratory to be susceptible to the antibiotics included in the empiric regimen. Inadequate empiric antibiotic therapy was defined by the presence of any bacterial isolate in numbers exceeding у10 5 cfu/ mL on culture of a BAL sample that was reported by the hospital microbiology laboratory to be intermediately resistant or resistant to the antibiotics included in the empiric regimen.
The variables identified as being potential risk factors for the development of S. maltophilia pneumonia were assessed by univariate analysis. Continuous data were compared by the Mann-Whitney U test or Student's t test, and categorical data were compared by x 2 test or Fisher's exact test, as appropriate. Variables for which were then included in a forward, P р .25 stepwise multiple logistic regression analysis to determine the independent variable and identify variables associated with the development of S. maltophilia pneumonia. Survival analysis by Kaplan-Meier estimation was used to compare patient outcomes; death and hospital discharge were used as censored variables, as appropriate. Continuous data are reported as or median (interquartile range [IQR]), as appromean ‫ע‬ SD priate, for parametrically and nonparametrically distributed data.
was considered to be statistically significant. P р .05
RESULTS
A total of 513 patient charts that listed a diagnosis of pneumonia were screened for enrollment. Of these patients, 163 met the study criteria and were included in the analysis. The remaining patients were excluded for the following reasons: visit of !7 days in the ICU ( ), patient had only early-onset n p 113 nosocomial pneumonia ( ), no episodes of pneumonia n p 105 fulfilled the study definition ( ), patient had only gramn p 81 positive late-onset pneumonia ( ), patient was not din p 20 rectly admitted to the ICU ( ), medical record was unn p 15 available ( ), late-onset pneumonia developed 15 days n p 8 after ICU transfer ( ), and patient was transferred to ann p 5 other hospital ICU ( ). n p 3 The demographic characteristics of the patients with SM-VAP were similar to those of the patients with GN-VAP (table  1) , with a trend toward more frequent chest injury in the SM-VAP group (80.8% vs. 59.9%;
) and more frequent P p .07 spinal cord injury in the GN-VAP group (19.7% vs. 3.8%;
). The overall prevalence of SM-VAP was 16% (26 of P p .09 163 patients). SM-VAP occurred in 14% of patients (18 of 130 patients) who experienced a single episode of late-onset nosocomial pneumonia and in 24% of patients (8 of 33 patients) who experienced multiple episodes. In the group of patients with multiple episodes of pneumonia, most experienced 2 episodes of late-onset nosocomial pneumonia (87.5% for SM-VAP and 64% for GN-VAP), and the remainder experienced 3 episodes. In addition, all episodes of SM-VAP were the last diagnosed pneumonia episode experienced by the patient before the end of the study period. Overall, pneumonia was polymicrobial in 46% (75 of 163) of the episodes; the frequency was significantly higher among episodes of SM-VAP than episodes of GN-VAP (92.3% vs.
37.2%;
). There were no differences in the distribution P ! .001 of bacterial species between the groups, except for a higher prevalence of Alcaligenes xylosoxidans among SM-VAP patients (23.1% for SM-VAP vs. 2.2% for GN-VAP; ) ( The overall mortality rate was 18.4% (30 of 163 patients); no significant difference was seen in mortality between the SM-VAP group and the GN-VAP group (23.1% vs. 17.5%; P p ). The Kaplan-Meier estimation curves for the SM-VAP and .69 GN-VAP groups are shown in figure 1A and 1B. There was no difference in mortality between the SM-VAP and GN-VAP groups ( ). However, SM-VAP patients were more likely P p .784 to continue to need mechanical ventilator support ( ; P p .025 figure 1A ) and to remain in the ICU ( ; figure 1B) , P p .047 with a trend toward increased length of hospital stay (P p ). . 064 The proportion of patients receiving inadequate empiric antibiotic therapy in the SM-VAP group was significantly higher than that in the GN-VAP group (93.2% vs. 43.8%; ; P ! .001 figure 1C) 
DISCUSSION
In this retrospective analysis of critically ill trauma patients, we identified cefepime exposure and the presence of a tracheostomy as the most significant factors associated with S. maltophilia pneumonia among patients who experienced a single episode of late-onset VAP. Among patients who experienced multiple episodes of late-onset pneumonia, higher ISS and the presence of a pulmonary contusion were most significantly associated with S. maltophilia pneumonia. The presence of central venous catheters [11] , previous antibiotic therapy [11, 12, [23] [24] [25] , severity of illness [24, 25] , and receipt of imipenem therapy [11, 26] have been identified as risk factors for S. maltophilia infection in various patient populations. Unfortunately, only 2 of those studies identified risk factors by multivariate analysis [11, 12] . These risk factors may not apply to the critically ill trauma patient, because patient characteristics, comorbidities, and treatment may differ significantly from those of nontrauma ICU patients. In addition, because nosocomial S. maltophilia infections typically are late-occurring, previous studies may have skewed the analysis of risk factors by including patients who were at low risk for S. maltophilia infection (i.e., patients with early-onset nosocomial pneumonia). Nonetheless, these results are consistent with risk factors for trauma patients with S. maltophilia colonization or infection [13] .
Villarino et al. [13] found that duration of mechanical ventilator support, presence of a tracheostomy, number of antimicrobial agents used, and use of air transport to the hospital were independent risk factors for S. maltophilia infection. Our study significantly adds to these results, because we excluded colonized patients, analyzed risk factors for pneumonia only, and used a more objective definition of pneumonia. In contrast to the findings of Villarino et al. [13] , the duration of mechanical ventilator support was not significantly associated with SM-VAP on multivariate analysis. This is most likely because we compared risk factors for SM-VAP against those for GN-VAP, which resulted in a more homogeneous group of patients. Previous antibiotic exposure, particularly to broad-spectrum antibiotics, has consistently correlated with S. maltophilia infections in trauma, medical ICU, and other patient populations [11, 12, 23, 24] . In particular, imipenem therapy has been associated with the emergence of S. maltophilia infections [11, 26] . Although we found that cefepime therapy posed a significant risk for S. maltophilia pneumonia on multivariate analysis, the identification of carbapenem use as a significant risk factor on univariate analysis supports the idea that exposure to broad-spectrum antibiotics may be more important than exposure to any single antibiotic agent. The association of cefepime with S. maltophilia pneumonia likely reflects the heavy use of this antibiotic as part of a standard empiric antibiotic regimen for treatment of late-onset nosocomial pneumonia within the Presley Memorial Trauma Center ICU. Previous studies have shown that imipenem and ceftazidime were associated with similar rates of S. maltophilia acquisition among hospitalized patients [27] .
Interestingly, the development of SM-VAP in patients with a single pneumonia episode was more strongly influenced by therapeutic interventions, whereas in multiple-episode pneumonia patients, SM-VAP was more strongly associated with severity of illness. In patients with a single episode of pneumonia, antibiotic exposure, number of BAL procedures, and presence of tracheostomy were associated with SM-VAP. It could be argued that the number of required BAL procedures and the need for tracheostomy may merely indicate greater severity of lung injury. However, there were no significant differences in indicators of chest injury such as chest AIS score, prevalence of thoracic injury, or requirement for thoracostomy. The finding that increased severity of injury was a significant risk factor for S. maltophilia infections is in agreement with findings that increased severity of illness is a risk factor in other ICU populations [4, 25] . The lack of association between therapeutic interventions and SM-VAP seen in the group of patients with multiple episodes of pneumonia likely is a result of the longer duration of ICU stay in that group, which increases the chance that patients in the SM-VAP and GN-VAP groups will have equal exposure to therapeutic interventions. Pulmonary contusion is known to be a risk factor for the development of nosocomial pneumonia [28] ; however, the present study is, to our knowledge, the first to identify it as a risk factor for S. maltophilia pneumonia. Other potential risk factors analyzed in the present study were not associated with increased risk of developing S. maltophilia pneumonia. In particular, the clinical presentation (temperature, WBC count, presence of purulent aspirates, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen) of S. maltophilia pneumonia was not different from that of pneumonia caused by other gram-negative bacteria, which indicates that the severity of illness is similar. Unfortunately, analyses of other factors, such as previous receipt of aerosolized medications, systemic glucocorticoid administration, medical history, and previous alcohol abuse and tobacco use, were limited by low statistical power and, thus, cannot be definitively excluded as risk factors.
S. maltophilia infection has been associated with increased mortality among patients with respiratory isolates [29] and bacteremia [30] . In our study, SM-VAP was not associated with higher mortality than GN-VAP. However, SM-VAP patients did have longer durations of mechanical ventilator support and ICU stay, with a trend toward a longer hospital stay than among GN-VAP patients. The ability to detect a difference, if any, in mortality among SM-VAP patients and GN-VAP patients may have been affected by the relatively high proportion of GN-VAP patients receiving inadequate empiric antibiotic therapy. Our results are consistent with previous reports that high mortality is associated with inadequate empiric antibiotic therapy Figure 1 . Kaplan-Meier curves for comparisons between groups of patients with ventilator-associated pneumonia. A, Probability that patients with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia (SM-VAP) and patients with ventilator-associated pneumonia caused by gram-negative pathogens other than S. maltophilia (GN-VAP) will continue to need mechanical ventilator support. B, Probability that patients with SM-VAP and GN-VAP will remain in the intensive care unit (ICU). C, Probability of survival for patients receiving adequate empiric antibiotic therapy and patients receiving inadequate empiric antibiotic therapy for ventilator-associated pneumonia.
in patients with pneumonia, and we extend this to the critically ill trauma patient [6, 8, 9] .
Currently, trimethoprim-sulfamethoxazole is the antibiotic of choice for treatment of S. maltophilia infections, because 190% of S. maltophilia isolates are susceptible to this combination [31, 32] . Because trimethoprim-sulfamethoxazole is bacteriostatic and lacks significant activity against other gramnegative bacteria, such as P. aeruginosa, it is not commonly used as empiric antibiotic therapy for nosocomial pneumonia. Ticarcillin-clavulanate and ceftazidime are potential alternatives, but, because only ∼50% of S. maltophilia isolates are susceptible to these drugs, their ability to provide adequate empiric coverage is limited [31, 32] . In vitro data suggest that the newer fluoroquinolones and doxycycline may be useful; however, clinical experience with these agents is sparse [33, 34] . Given the relative lack of agents that have significant activity against S. maltophilia, it is not surprising that the majority of SM-VAP patients in our study did not receive adequate empiric antibiotic therapy. An appropriate conclusion may be that patients do not die as a result of S. maltophilia pneumonia but, rather, as a result of the lack of adequate empiric antibiotic therapy associated with S. maltophilia pneumonia. Given the deleterious outcomes, it seems reasonable to include trimethoprim-sulfamethoxazole as empiric antibiotic therapy in treatment of patients with the risk factors we have identified.
In addition to the previously discussed limitations, the effect of the retrospective nature of the data collection on our results must be considered. The results of this study should only be applied to the critically ill trauma patient, because the mechanism of injury, younger age, and infrequency of comorbid conditions in this group renders such patients distinctly different from other ICU populations. In addition, in ICUs with a low prevalence of S. maltophilia pneumonia, the risk of severe allergic reactions and the risk associated with large intravenous volume administration may outweigh the benefits associated with trimethoprim-sulfamethoxazole therapy. Although we identified a significant association between exposure to cefepime and carbapenem antibiotics and S. maltophilia pneumonia, proper evaluation of other antibiotics or antibiotic classes was limited by low statistical power. Therefore, we cannot definitively exclude the possibility that exposure to other antibiotics is a risk factor for S. maltophilia pneumonia. Further risk-factor analysis for S. maltophilia pneumonia in patients with multiple episodes of pneumonia may be warranted, because the present study included relatively few patients and, thus, could have missed other important risk factors or produced spurious findings. A study of at least 10 patients per variable would be required to validate our results. Finally, in the univariate analysis, a type 1 error may have occurred as a result of the multiple comparisons required to analyze all potential risk factors.
In conclusion, risk factors for the emergence of S. maltophilia pneumonia were identified in critically ill trauma patients with late-onset nosocomial pneumonia. Stenotrophomonas pneumonia was associated with increased morbidity but not increased mortality, whereas inadequate empiric antibiotic therapy was associated with increased mortality but had no effect on morbidity. As a result of the high intrinsic resistance of S. maltophilia to most antibiotics, patients with S. maltophilia pneumonia commonly receive inadequate empiric antibiotic therapy. Consequently, empiric antibiotic therapy for patients with suspected late-onset VAP and patients with the risk factors we have identified should include agents (preferably trimethoprim-sulfamethoxazole) with activity against S. maltophilia.
